We intercept disease-driving kinases where they are unguarded:
the metastable OFF-state regime


Unlike classical inhibitors that target kinases when they are fully folded and activated (ON), T6TCs* typify an emerging class of small molecules capable of targeting kinases in idle, metastable conformations (OFF), which are far removed from downstream signaling nodes.


While classical kinase inhibitors are very effective at inhibiting the ON-state, they are conceptually bound to also facilitate escape to treatment (Arora et al., Cell, 2023).


T6TCs intercept kinases upstream of signaling nodes, denying tumors access to habitual escape routes.

*T6TC: Type6 Tx Compound

Classical inhibitor design benefits from a rich data space around the ON-state, yet tumors escape
Type6 inhibitors provide exclusive access to the OFF-state regime, with vastly improved outcomes